RoseRx logo — A clinical-first, patient-centric platform that empowers pat...

RoseRx

A clinical-first, patient-centric platform that empowers patient action & improve access to life changing treatment.

Founded 2020 Australia Australia 13 employees Series A Total: $11.84M Biopharma, Health Care +1

General Information

Company Name RoseRx
Founded Year 2020
Location Australia Australia
Employees 13
Industries Biopharma, Health Care, Life Sciences
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with RoseRx. To contact RoseRx, visit roserx.health.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About RoseRx

RoseRx is a revolutionary startup that was founded in 2020 and is based in Australia. The company's mission is encapsulated in its slogan, "A clinical-first, patient-centric platform that empowers patient action & improve access to life-changing treatment." RoseRx operates at the intersection of the Biopharma and Health Care industries. At the core of its operations, RoseRx assists individuals in navigating their health on a large scale. The platform achieves this by ethically empowering patients to take action, thereby accelerating their journey to access life-changing treatment. In September 2021, RoseRx secured a significant $6.65M Series A investment from renowned venture capital firm, Breyer Capital. The company's approach is singularly focused on patient empowerment and improving the accessibility of transformative healthcare solutions. RoseRx's commitment to facilitating patient action and enhancing access to life-changing treatments positions it as an innovative leader within the healthcare space. For further details, visit the company's website.

Taxonomy: clinical-first platform, patient-centric, healthcare navigation, access to treatment, patient action, ethical empowerment, health technology, patient journey, treatment access

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $6.65M 1
Breyer Capital
08 Sep 2021
Seed Round Undisclosed 2
Artesian, Breyer Capital
04 Nov 2020
Seed Round $5.19M 4
Artesian, Breyer Capital +2
07 Jul 2020

RoseRx Alternatives & Competitors

View All Alternatives
RoseRx vs

Clinical Research, Re-Engineered
for Impact

Series A
144 employees
Health Care, Life Sciences
RoseRx vs
Genome Medical
Genome Medical United States

Enabling a world where everyone’s health is informed by genetics

Series C
122 employees
Health Care, Life Sciences
RoseRx vs
uMed
uMed United States

Addressing Evidence Gaps in Life Science Research

Series A
65 employees
Digital Health, Health Care

FAQ About RoseRx

A clinical-first, patient-centric platform that empowers patient action & improve access to life changing treatment.
RoseRx was founded in 2020.
RoseRx is headquartered in Australia.
RoseRx operates in Biopharma, Health Care and Life Sciences. Its work centres on clinical-first platform, patient-centric, healthcare navigation and access to treatment.
RoseRx has approximately 13 employees.
RoseRx has completed 3 funding rounds, raising a total of $11.84M. The latest funding stage is Series A.
Top alternatives and competitors to RoseRx include Paradigm Health, Genome Medical, uMed, AayushBharat, OASYS NOW. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RoseRx and Paradigm Health are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for RoseRx, https://bouncewatch.com/company/roserx, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes